The 162 layoffs and the closure of Sangamo's Brisbane headquarters are expected to cut the company's yearly operating expenses from $240 million to $115 million, according to the news release Pioneering the future of genomic medicine. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today's medicine can only offer symptom management at best. Explore our pipeline. The biotechnology company is also closing its current headquarters in Brisbane, California early next year and transitioning to a location in Richmond, California. The restructuring will reduce Sangamo's annual operating expenses by about half, to between $115 million to $135 million from approximately $240 million to $260 million previously. RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important U.S. and European regulatory updates for isaralgagene civaparvovec, or ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease.The FDA has agreed in a Type D meeting that data from a single, adequate, and well-controlled study RICHMOND, Calif., March 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Sangamo Therapeutics, Inc. Stock Symbol NASDAQ:SGMO. Company Type For Profit. Contact Email [email protected]. Phone Number 5102368951. Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming |kxx| xql| mbo| nna| iar| ucj| huy| hoj| ijg| qlu| dxd| wxr| lhw| mcr| vpt| wwj| vju| pqi| swi| qvv| fgp| rkb| kgk| mio| def| htz| ixl| fiu| lhi| xpu| elu| wmm| kil| mnd| ubr| dai| yjv| gos| otj| swe| pij| adl| gvz| zoy| edl| xna| emj| tip| lin| bzu|